AAPL336.64-3.78 (-1.11%) ▼|ABBV276.47+4.05 (+1.49%) ▲|ABT99.60+1.11 (+1.13%) ▲|ACN209.06+0.70 (+0.34%) ▲|ADBE242.27+1.22 (+0.51%) ▲|AMAT507.03-2.54 (-0.50%) ▼|AMD608.10-12.58 (-2.03%) ▼|AMGN414.87+7.43 (+1.82%) ▲|AMT182.24+15.51 (+9.30%) ▲|AMZN262.43+8.37 (+3.29%) ▲|AVGO361.54+1.40 (+0.39%) ▲|AXP308.17+1.02 (+0.33%) ▲|BA190.37+2.62 (+1.40%) ▲|BAC54.32+0.71 (+1.32%) ▲|BKNG160.34+0.37 (+0.23%) ▲|BLK1,082.39+17.04 (+1.60%) ▲|BMY59.12-0.46 (-0.77%) ▼|BNY142.71-0.90 (-0.63%) ▼|BRK-B515.62+4.57 (+0.89%) ▲|C129.64+1.56 (+1.22%) ▲|CAT800.47+4.29 (+0.54%) ▲|CL88.27+0.17 (+0.19%) ▲|CMCSA20.66-0.55 (-2.59%) ▼|COF199.26-0.14 (-0.07%) ▼|COP134.10-0.09 (-0.07%) ▼|COST946.92-1.00 (-0.11%) ▼|CRM229.13+1.33 (+0.58%) ▲|CSCO118.39+3.50 (+3.05%) ▲|CVS86.16-1.64 (-1.87%) ▼|CVX211.98+0.43 (+0.20%) ▲|DE620.93-31.65 (-4.85%) ▼|DHR219.81+2.35 (+1.08%) ▲|DIS108.05+1.03 (+0.96%) ▲|DUK116.65-0.19 (-0.16%) ▼|EMR161.83+2.77 (+1.74%) ▲|FDX291.71-0.02 (-0.01%) ▼|GD331.27+2.96 (+0.90%) ▲|GE308.20+2.58 (+0.84%) ▲|GEV1,004.73+5.38 (+0.54%) ▲|GILD151.17+4.07 (+2.77%) ▲|GM82.73+0.48 (+0.58%) ▲|GOOG347.86+3.00 (+0.87%) ▲|GOOGL351.66+3.37 (+0.97%) ▲|GS895.32+12.73 (+1.44%) ▲|HD290.74-4.73 (-1.60%) ▼|HON207.73+1.13 (+0.55%) ▲|IBM227.13+0.52 (+0.23%) ▲|INTC104.70-2.38 (-2.22%) ▼|INTU302.75-1.13 (-0.37%) ▼|ISRG423.96+8.55 (+2.06%) ▲|JNJ261.44+4.96 (+1.93%) ▲|JPM332.99+1.57 (+0.47%) ▲|KO88.05+0.28 (+0.32%) ▲|LIN483.73+2.03 (+0.42%) ▲|LLY1,179.27+9.67 (+0.83%) ▲|LMT509.59+1.70 (+0.33%) ▲|LOW186.00-2.85 (-1.51%) ▼|LRCX318.84-1.75 (-0.55%) ▼|MA589.14+15.25 (+2.66%) ▲|MCD235.23-1.67 (-0.70%) ▼|MDLZ60.41-0.26 (-0.43%) ▼|MDT88.48+0.73 (+0.83%) ▲|META718.67-2.22 (-0.31%) ▼|MMM159.96-3.62 (-2.21%) ▼|MO71.68+0.26 (+0.36%) ▲|MRK145.60+3.22 (+2.26%) ▲|MS190.02+2.58 (+1.38%) ▲|MSFT535.07+12.46 (+2.38%) ▲|MU1,029.00-6.84 (-0.66%) ▼|NEE77.38+0.01 (+0.01%) ▲|NFLX70.30-1.27 (-1.77%) ▼|NKE34.71-0.03 (-0.09%) ▼|NOW140.86+1.11 (+0.79%) ▲|NVDA229.28-1.20 (-0.52%) ▼|ORCL141.40+6.21 (+4.59%) ▲|PEP125.97-2.37 (-1.85%) ▼|PFE28.28+0.46 (+1.65%) ▲|PG151.23+0.64 (+0.43%) ▲|PLTR209.05+10.27 (+5.17%) ▲|PM201.19+0.69 (+0.34%) ▲|QCOM175.50-0.51 (-0.29%) ▼|RTX185.97+1.65 (+0.90%) ▲|SBUX90.75-2.46 (-2.64%) ▼|SCHW96.70-0.17 (-0.18%) ▼|SO86.17+0.02 (+0.02%) ▲|SPG199.42-0.19 (-0.10%) ▼|T22.18-2.41 (-9.81%) ▼|TMO658.02+6.04 (+0.93%) ▲|TMUS148.58-22.73 (-13.27%) ▼|TSLA382.70+7.70 (+2.05%) ▲|TXN283.74-4.46 (-1.55%) ▼|UBER71.51+1.27 (+1.81%) ▲|UNH379.30+8.35 (+2.25%) ▲|UNP278.34+0.14 (+0.05%) ▲|UPS94.57+0.44 (+0.47%) ▲|USB57.08+0.05 (+0.09%) ▲|V385.45+10.35 (+2.76%) ▲|VZ41.65-3.99 (-8.75%) ▼|WFC83.55+1.52 (+1.85%) ▲|WMT111.35+0.79 (+0.71%) ▲|XOM168.94+0.44 (+0.26%) ▲|AAPL336.64-3.78 (-1.11%) ▼|ABBV276.47+4.05 (+1.49%) ▲|ABT99.60+1.11 (+1.13%) ▲|ACN209.06+0.70 (+0.34%) ▲|ADBE242.27+1.22 (+0.51%) ▲|AMAT507.03-2.54 (-0.50%) ▼|AMD608.10-12.58 (-2.03%) ▼|AMGN414.87+7.43 (+1.82%) ▲|AMT182.24+15.51 (+9.30%) ▲|AMZN262.43+8.37 (+3.29%) ▲|AVGO361.54+1.40 (+0.39%) ▲|AXP308.17+1.02 (+0.33%) ▲|BA190.37+2.62 (+1.40%) ▲|BAC54.32+0.71 (+1.32%) ▲|BKNG160.34+0.37 (+0.23%) ▲|BLK1,082.39+17.04 (+1.60%) ▲|BMY59.12-0.46 (-0.77%) ▼|BNY142.71-0.90 (-0.63%) ▼|BRK-B515.62+4.57 (+0.89%) ▲|C129.64+1.56 (+1.22%) ▲|CAT800.47+4.29 (+0.54%) ▲|CL88.27+0.17 (+0.19%) ▲|CMCSA20.66-0.55 (-2.59%) ▼|COF199.26-0.14 (-0.07%) ▼|COP134.10-0.09 (-0.07%) ▼|COST946.92-1.00 (-0.11%) ▼|CRM229.13+1.33 (+0.58%) ▲|CSCO118.39+3.50 (+3.05%) ▲|CVS86.16-1.64 (-1.87%) ▼|CVX211.98+0.43 (+0.20%) ▲|DE620.93-31.65 (-4.85%) ▼|DHR219.81+2.35 (+1.08%) ▲|DIS108.05+1.03 (+0.96%) ▲|DUK116.65-0.19 (-0.16%) ▼|EMR161.83+2.77 (+1.74%) ▲|FDX291.71-0.02 (-0.01%) ▼|GD331.27+2.96 (+0.90%) ▲|GE308.20+2.58 (+0.84%) ▲|GEV1,004.73+5.38 (+0.54%) ▲|GILD151.17+4.07 (+2.77%) ▲|GM82.73+0.48 (+0.58%) ▲|GOOG347.86+3.00 (+0.87%) ▲|GOOGL351.66+3.37 (+0.97%) ▲|GS895.32+12.73 (+1.44%) ▲|HD290.74-4.73 (-1.60%) ▼|HON207.73+1.13 (+0.55%) ▲|IBM227.13+0.52 (+0.23%) ▲|INTC104.70-2.38 (-2.22%) ▼|INTU302.75-1.13 (-0.37%) ▼|ISRG423.96+8.55 (+2.06%) ▲|JNJ261.44+4.96 (+1.93%) ▲|JPM332.99+1.57 (+0.47%) ▲|KO88.05+0.28 (+0.32%) ▲|LIN483.73+2.03 (+0.42%) ▲|LLY1,179.27+9.67 (+0.83%) ▲|LMT509.59+1.70 (+0.33%) ▲|LOW186.00-2.85 (-1.51%) ▼|LRCX318.84-1.75 (-0.55%) ▼|MA589.14+15.25 (+2.66%) ▲|MCD235.23-1.67 (-0.70%) ▼|MDLZ60.41-0.26 (-0.43%) ▼|MDT88.48+0.73 (+0.83%) ▲|META718.67-2.22 (-0.31%) ▼|MMM159.96-3.62 (-2.21%) ▼|MO71.68+0.26 (+0.36%) ▲|MRK145.60+3.22 (+2.26%) ▲|MS190.02+2.58 (+1.38%) ▲|MSFT535.07+12.46 (+2.38%) ▲|MU1,029.00-6.84 (-0.66%) ▼|NEE77.38+0.01 (+0.01%) ▲|NFLX70.30-1.27 (-1.77%) ▼|NKE34.71-0.03 (-0.09%) ▼|NOW140.86+1.11 (+0.79%) ▲|NVDA229.28-1.20 (-0.52%) ▼|ORCL141.40+6.21 (+4.59%) ▲|PEP125.97-2.37 (-1.85%) ▼|PFE28.28+0.46 (+1.65%) ▲|PG151.23+0.64 (+0.43%) ▲|PLTR209.05+10.27 (+5.17%) ▲|PM201.19+0.69 (+0.34%) ▲|QCOM175.50-0.51 (-0.29%) ▼|RTX185.97+1.65 (+0.90%) ▲|SBUX90.75-2.46 (-2.64%) ▼|SCHW96.70-0.17 (-0.18%) ▼|SO86.17+0.02 (+0.02%) ▲|SPG199.42-0.19 (-0.10%) ▼|T22.18-2.41 (-9.81%) ▼|TMO658.02+6.04 (+0.93%) ▲|TMUS148.58-22.73 (-13.27%) ▼|TSLA382.70+7.70 (+2.05%) ▲|TXN283.74-4.46 (-1.55%) ▼|UBER71.51+1.27 (+1.81%) ▲|UNH379.30+8.35 (+2.25%) ▲|UNP278.34+0.14 (+0.05%) ▲|UPS94.57+0.44 (+0.47%) ▲|USB57.08+0.05 (+0.09%) ▲|V385.45+10.35 (+2.76%) ▲|VZ41.65-3.99 (-8.75%) ▼|WFC83.55+1.52 (+1.85%) ▲|WMT111.35+0.79 (+0.71%) ▲|XOM168.94+0.44 (+0.26%) ▲|
14.7 C
New York
Monday, October 12, 2026

Tag: company

INVESTOR ALERT: Investigation of Replimune Group, Inc. (REPL) Announced by Holzer & Holzer, LLC

ATLANTA, July 22, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL) complied with federal securities laws. On July 22, 2025, Replimune announced it received a Complete Response Letter (“CRL”) from the FDA regarding the Biologics License Application (“BLA”) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma. In the CRL, the FDA indicated “that the IGNYTE trial is not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness.” Following this news, the price of the Company’s stock dropped. 

IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4849), a Potential First-in-Class DLL3-TOP1 ADC

Clinical efficacy and safety data will be presented from over 70 small-cell lung cancer (SCLC) patients in Hengrui's ongoing, multi-site, open label Phase 1...

Roche’s Board of Directors proposes exchange of Genussscheine for participation certificates (Partizipationsscheine)

Basel, 22 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today its Board of Directors' decision to propose to shareholders a modernisation of Roche Holding Ltd’s capital structure for approval at the Annual General Meeting to be held on 10 March 2026 ("2026 AGM"). The proposal includes the exchange of the existing non-voting equity securities (“Genussscheine”) for participation certificates with a nominal value of CHF 0.001 each.

Transaction in Own Shares

Transaction in Own Shares

Stardog Appoints Sara Golbourn as Chief Revenue Officer to Scale the Enterprise Answer Engine

Stardog Appoints Sara Golbourn as Chief Revenue Officer to Scale the Enterprise Answer Engine

Somatus Surpasses 500,000 Patients Actively Under Management Across All 50 States and DC

Value-based kidney care leader expands capabilities in CHF care management, commercial self-insured populations, and AI-driven disease identification and payment integrity services MCLEAN, Va., July 22,...

QNB Corp. Reports Earnings for Second Quarter 2025

QUAKERTOWN, Pa., July 22, 2025 (GLOBE NEWSWIRE) -- QNB Corp. (the “Company” or “QNB”) (OTCQX: QNBC), the parent company of QNB Bank (the “Bank”), reported net income for the second quarter of 2025 of $3,883,000 or $1.04 per share on a diluted basis. This compares to net income of $2,465,000, or $0.67 per share on a diluted basis, for the same period in 2024. For the six months ended June 30, 2025, QNB reported net income of $6,461,000, or $1.74 per share on a diluted basis. This compares to net income of $5,059,000, or $1.38 per share on a diluted basis, reported for the same period in 2024.

Adam Breen Joins Accruit as Vice President of Product and Strategy

Accomplished Product and Strategy Executive joins Accruit's Senior Leadership Team to Drive Product Innovation and Advance Technology Strategy DENVER, July 22, 2025 /PRNewswire/ -- Accruit,...

Christian Brothers Automotive Honored with Franchise Update Media 2025 Franchise Innovation Award

7th annual contest celebrates excellence in innovation HOUSTON, July 22, 2025 /PRNewswire/ -- Franchise Update Media conducted its 7th annual Franchise Innovation Awards contest this...

AEP Declares Quarterly Dividend on Common Stock

COLUMBUS, Ohio, July 22, 2025 /PRNewswire/ -- The Board of Directors of American Electric Power (Nasdaq: AEP) has declared a regular quarterly cash dividend...

New England Biolabs® launches NEBNext® Low-bias Small RNA Library Prep Kit, presenting a new method for capturing the true diversity of RNA samples

Original research by NEB scientists contributes to the kit's unprecedented low bias,speed, shelf life, and input range IPSWICH, Mass., July 22, 2025 /PRNewswire/ -- New England Biolabs...

Stoneridge, Inc. To Broadcast Its Second Quarter 2025 Conference Call On The Web

NOVI, Mich., July 22, 2025 /PRNewswire/ -- Stoneridge, Inc. (NYSE: SRI) will webcast its second quarter 2025 earnings conference call live on Thursday, August...

Get Your Car Ready for College

Mercury Insurance Provides a Checklist to Make Sure You're Prepared LOS ANGELES, July 22, 2025 /PRNewswire/ -- We are approaching that time of year when college...

ECGI’s Uplist Ventures Accepted to TCA, Unlocking Access to Elite Startup Ecosystem

IRVINE, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- via IBN -- ECGI Holdings Inc. (OTC: ECGI), a diversified holding company focused on innovation and growth, today announced that its investment arm, Uplist Ventures, was accepted as an affiliate member of TCA Venture Group (formerly Tech Coast Angels). This move positions Uplist Ventures to access one of the most active angel investor networks in the United States, providing exclusive visibility into high-quality early- and growth-stage opportunities.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsCompany